DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS
    1.
    发明申请
    DIRECTED EVOLUTION OF NOVEL BINDING PROTEINS 审中-公开
    新型结合蛋白的指导进化

    公开(公告)号:US20070259417A1

    公开(公告)日:2007-11-08

    申请号:US11745199

    申请日:2007-05-07

    IPC分类号: C12N1/08

    摘要: In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

    摘要翻译: 为了获得针对所选靶标的新型结合蛋白,每个编码包含相似潜在结合结构域的家族之一的蛋白质的DNA分子和要求在选择的细菌细胞的外表面上显示蛋白质的结构信号 ,细菌孢子或噬菌体(遗传包装)被引入到遗传包装中。 蛋白质被表达,并且潜在的结合结构域显示在包装的外表面上。 分离和扩增具有识别靶分子的结合域的细胞或病毒。 然后表征成功的结合结构域。 将这些成功结合结构域中的一个或多个用作设计新的潜在结合结构域家族的模型,并重复该过程,直到获得对靶分子具有所需亲和力的新结合结构域。 在一个实施方案中,第一潜在结合域家族与牛胰蛋白酶抑制剂有关,遗传包是M13噬菌体,蛋白质包括M13基因III蛋白的外表面转运信号。

    Directed evolution of disulfide-bonded micro-proteins
    3.
    发明申请
    Directed evolution of disulfide-bonded micro-proteins 有权
    二硫键结合微蛋白的定向进化

    公开(公告)号:US20060084113A1

    公开(公告)日:2006-04-20

    申请号:US10207797

    申请日:2002-07-31

    IPC分类号: C40B40/10

    CPC分类号: C12N15/1037 C40B40/02

    摘要: In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

    摘要翻译: 为了获得针对所选靶标的新型结合蛋白,每个编码包含相似潜在结合结构域的家族之一的蛋白质的DNA分子和要求在选择的细菌细胞的外表面上显示蛋白质的结构信号 ,细菌孢子或噬菌体(遗传包装)被引入到遗传包装中。 蛋白质被表达,并且潜在的结合结构域显示在包装的外表面上。 分离和扩增具有识别靶分子的结合域的细胞或病毒。 然后表征成功的结合结构域。 将这些成功结合结构域中的一个或多个用作设计新的潜在结合结构域家族的模型,并重复该过程,直到获得对靶分子具有所需亲和力的新结合结构域。 在一个实施方案中,第一潜在结合域家族与牛胰蛋白酶抑制剂有关,遗传包是M13噬菌体,蛋白质包括M13基因III蛋白的外表面转运信号。

    INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS
    6.
    发明申请
    INHIBITORS OF HUMAN PLASMIN DERIVED FROM THE KUNITZ DOMAINS 审中-公开
    人类血清抑制剂从昆虫域传播

    公开(公告)号:US20110152193A1

    公开(公告)日:2011-06-23

    申请号:US13034967

    申请日:2011-02-25

    IPC分类号: A61K38/16 A61P7/00 A61P7/04

    CPC分类号: C04B35/5935 C07K14/8114

    摘要: This invention provides: novel proteins, which are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and which are capable of inhibiting plasmin; uses of such novel proteins in therapeutic, diagnostic, and clinical methods; and polynucleotides that encode such novel proteins.

    摘要翻译: 本发明提供了与脂蛋白相关凝血抑制剂(LACI)的第一Kunitz结构域(K1)同源的能够抑制纤溶酶的新型蛋白质; 在治疗,诊断和临床方法中使用这种新型蛋白质; 和编码这种新蛋白质的多核苷酸。

    Method for changing threshold voltage of device in resist asher
    7.
    发明授权
    Method for changing threshold voltage of device in resist asher 有权
    改变抗蚀剂装置的阈值电压的方法

    公开(公告)号:US07256094B2

    公开(公告)日:2007-08-14

    申请号:US11136131

    申请日:2005-05-24

    IPC分类号: H01L21/336

    CPC分类号: H01L21/31138 H01L21/2236

    摘要: A method for forming a dopant in a substrate, by accumulating at least one dopant species in an asher chamber and forming the accumulated dopant species on an exposed portion of the substrate. A target concentration for the plasma chamber dopant species is determined by test or measurement. The asher is used to form the dopant species on the substrate, and the dopant species is driven into the substrate. A threshold voltage is measured on the substrate to verify or confirm that a proper dopant level has been achieved.

    摘要翻译: 一种在衬底中形成掺杂剂的方法,其通过在所述衬底室中积聚至少一种掺杂剂物质并在所述衬底的暴露部分上形成所述累积的掺杂剂物质。 通过测试或测量确定等离子体室掺杂剂物质的目标浓度。 灰浆用于在衬底上形成掺杂剂物质,并且掺杂剂物质被驱动到衬底中。 在衬底上测量阈值电压以验证或确认已经实现了适当的掺杂剂水平。